MX2019006141A - Metodos para tratar trastornos inflamatorios con compuestos de fc multivalentes. - Google Patents

Metodos para tratar trastornos inflamatorios con compuestos de fc multivalentes.

Info

Publication number
MX2019006141A
MX2019006141A MX2019006141A MX2019006141A MX2019006141A MX 2019006141 A MX2019006141 A MX 2019006141A MX 2019006141 A MX2019006141 A MX 2019006141A MX 2019006141 A MX2019006141 A MX 2019006141A MX 2019006141 A MX2019006141 A MX 2019006141A
Authority
MX
Mexico
Prior art keywords
methods
multivalent
compounds
inflammatory disorders
treating inflammatory
Prior art date
Application number
MX2019006141A
Other languages
English (en)
Inventor
S Block David
Olsen Henrik
Original Assignee
Gliknik Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gliknik Inc filed Critical Gliknik Inc
Publication of MX2019006141A publication Critical patent/MX2019006141A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Abstract

La presente invención provee métodos para la identificación de pacientes con una enfermedad autoinmunitaria o inflamatoria que demuestran una respuesta inadecuada al tratamiento con un agente terapéutico multi-Fc y la determinación de una dosis óptima de un agente terapéutico multi-Fc para dicho paciente con base en los niveles en circulación del paciente de C3b inactivado (iC3b) y/o componentes del complemento adicionales que se pueden emplear como un sustituto para iC3b con base en una respuesta análoga a los agentes terapéuticos multi-Fc. La presente invención provee además mejoras en el uso de tales agentes terapéuticos multi-Fc en el tratamiento de enfermedades autoinmunitarias e inflamatorias.
MX2019006141A 2016-12-09 2017-12-08 Metodos para tratar trastornos inflamatorios con compuestos de fc multivalentes. MX2019006141A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662432407P 2016-12-09 2016-12-09
PCT/US2017/065400 WO2018107082A1 (en) 2016-12-09 2017-12-08 Methods of treating inflammatory disorders with multivalent fc compounds

Publications (1)

Publication Number Publication Date
MX2019006141A true MX2019006141A (es) 2019-08-14

Family

ID=62491402

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019006141A MX2019006141A (es) 2016-12-09 2017-12-08 Metodos para tratar trastornos inflamatorios con compuestos de fc multivalentes.

Country Status (11)

Country Link
US (2) US11331372B2 (es)
EP (1) EP3551227A4 (es)
JP (2) JP2020500856A (es)
KR (1) KR20190093186A (es)
CN (1) CN110022898B (es)
AU (1) AU2017371182B2 (es)
BR (1) BR112019009495A2 (es)
CA (1) CA3043251A1 (es)
IL (1) IL266988A (es)
MX (1) MX2019006141A (es)
WO (1) WO2018107082A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190095929A (ko) 2016-12-09 2019-08-16 글리크닉 인코포레이티드 다합체화 스트라도머인 gl-2045의 제조 최적화
WO2018107082A1 (en) 2016-12-09 2018-06-14 Gliknik Inc. Methods of treating inflammatory disorders with multivalent fc compounds
JP2021530992A (ja) * 2018-07-11 2021-11-18 モメンタ ファーマシューティカルズ インコーポレイテッド 改変されたＦｃ抗原結合ドメイン構築体に関する組成物および方法
WO2020014526A2 (en) * 2018-07-11 2020-01-16 Anthony Manning Compositions and methods related to engineered fc-antigen binding domain constructs targeted to cd38

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0680337A4 (en) 1993-01-12 1997-07-30 Anthony George Gristina METHODS AND COMPOSITIONS FOR DIRECT APPLICATION WITH HIGH CONCENTRATION OF ANTIBODIES, PRODUCING PASSIVE IMMUNITY.
US20020147326A1 (en) 1996-06-14 2002-10-10 Smithkline Beecham Corporation Hexameric fusion proteins and uses therefor
CA2341029A1 (en) 1998-08-17 2000-02-24 Abgenix, Inc. Generation of modified molecules with increased serum half-lives
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
WO2002056910A1 (en) 2001-01-17 2002-07-25 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
DK1366067T3 (da) 2001-03-07 2012-10-22 Merck Patent Gmbh Ekspressionsteknologi for proteiner indeholdende en hybrid isotype-antistof-enhed
CA2437958C (en) 2001-03-09 2018-10-30 University Of Chicago Polymeric immunoglobulin fusion proteins that target low-affinity fc.gamma.receptors
KR100453877B1 (ko) 2001-07-26 2004-10-20 메덱스젠 주식회사 연쇄체화에 의한 면역 글로블린 융합 단백질의 제조 방법 및 이 방법에 의해 제조된 ＴＮＦＲ/Ｆｃ 융합 단백질, 상기 단백질을 코딩하는 ＤＮＡ, 상기 ＤＮＡ를 포함하는벡터, 및 상기 벡터에 의한 형질전환체
WO2003074679A2 (en) 2002-03-01 2003-09-12 Xencor Antibody optimization
WO2006061650A2 (en) 2004-12-10 2006-06-15 Trigen Gmbh Methods, products and uses involving platelets and/or the vasculature
WO2003105898A1 (en) 2002-06-14 2003-12-24 Centocor, Inc. Modified "s" antibodies
DK1569685T3 (da) 2002-11-15 2012-11-12 Univ Colorado Regents Komplementmodulatorer rettet mod komplementreceptor-2
US7348004B2 (en) 2003-05-06 2008-03-25 Syntonix Pharmaceuticals, Inc. Immunoglobulin chimeric monomer-dimer hybrids
JP2007501021A (ja) 2003-05-30 2007-01-25 アレクシオン ファーマシューティカルズ， インコーポレイテッド 遺伝子操作された定常領域を含む、抗体および融合タンパク質
DE602004026724D1 (de) 2003-06-13 2010-06-02 Univ Pittsburgh Überwachung von immunologischen, hämatologischen und entzündlichen erkrankungen
AU2004321500A1 (en) 2003-09-29 2006-05-11 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Immunoglobulins with potent and broad antiviral activity
EP1697520A2 (en) 2003-12-22 2006-09-06 Xencor, Inc. Fc polypeptides with novel fc ligand binding sites
WO2005089503A2 (en) 2004-03-19 2005-09-29 Progenics Pharmaceuticals, Inc. Cd4-igg2 formulations
AU2005264159A1 (en) 2004-07-19 2006-01-26 Elutex Ltd. Modified conductive surfaces having active substances attached thereto
US20060074225A1 (en) 2004-09-14 2006-04-06 Xencor, Inc. Monomeric immunoglobulin Fc domains
US7968316B2 (en) 2005-08-16 2011-06-28 Hanmi Holdings Co., Ltd. Method for the mass production of immunoglobulin Fc region deleted initial methionine residues
EP2144930A1 (en) 2007-04-18 2010-01-20 ZymoGenetics, Inc. Single chain fc, methods of making and methods of treatment
AU2008260498B2 (en) 2007-05-30 2012-11-29 Xencor, Inc. Methods and compositions for inhibiting CD32b expressing cells
EP2641913B1 (en) 2007-06-01 2018-04-18 University of Maryland, Baltimore Immunoglobulin constant region Fc receptor binding agents
CA2911256A1 (en) 2008-10-20 2010-12-09 Robert K. Hickman Isolation and purification of antibodies using protein a affinity chromatography
WO2010065578A2 (en) 2008-12-04 2010-06-10 Leukosight Inc. POLYPEPTIDES COMPRISING Fc FRAGMENTS OF IMMUNOGLOBULIN G (IgG) AND METHODS OF USING THE SAME
US20120100140A1 (en) 2009-01-23 2012-04-26 Biogen Idec Ma Inc. Stabilized fc polypeptides with reduced effector function and methods of use
CN102405232B (zh) 2009-02-19 2015-08-19 葛兰素集团有限公司 改良的抗血清清蛋白结合变体
GB0922209D0 (en) 2009-12-18 2010-02-03 Univ Nottingham Proteins, nucleic acid molecules and compositions
KR20130036276A (ko) * 2010-06-22 2013-04-11 더 리젠츠 오브 더 유니버시티 오브 콜로라도, 어 바디 코포레이트 보체 결합 3의 C3d 조각에 대한 항체들
AU2015200330B2 (en) 2010-07-28 2016-10-27 Gliknik Inc. Fusion proteins of natural human protein fragments to create orderly multimerized immunoglobulin Fc compositions
TWI588157B (zh) 2010-07-28 2017-06-21 吉林尼克公司 產生依序多聚體化免疫球蛋白ｆｃ組合物之天然人類蛋白質片段之融合蛋白
US8865164B2 (en) * 2010-11-02 2014-10-21 Kypha, Inc. Detecting complement activation
CA2871910C (en) 2012-05-01 2021-08-10 Kypha, Inc. Detecting complement activation
WO2013176754A1 (en) 2012-05-24 2013-11-28 Abbvie Inc. Novel purification of antibodies using hydrophobic interaction chromatography
PT2692865E (pt) 2012-07-30 2015-02-06 Nbe Therapeutics Llc Identificação mediada por transposição de proteínas funcionais ou de ligação específicas
MX2015002269A (es) 2012-08-20 2015-07-06 Gliknik Inc Moleculas con actividad de union al antigeno y al receptor fc gamma polivalente.
EP2908914B1 (en) 2012-10-17 2018-04-18 Liverpool School of Tropical Medicine Immunomodulatory proteins
WO2014082083A1 (en) 2012-11-26 2014-05-30 Caris Science, Inc. Biomarker compositions and methods
US20150038682A1 (en) 2013-08-02 2015-02-05 Jn Biosciences Llc Antibodies or fusion proteins multimerized via homomultimerizing peptide
WO2015070041A1 (en) * 2013-11-08 2015-05-14 Icahn School Of Medicine At Mount Sinai Methods for monitoring kidney dysfunction
AU2015226100B2 (en) 2014-03-05 2020-05-07 UCB Biopharma SRL Multimeric Fc proteins
BR112016020377A2 (pt) 2014-03-05 2018-01-23 Ucb Biopharma Sprl proteínas fc multiméricas
BR112016023948A2 (pt) 2014-04-16 2018-01-30 Ucb Biopharma Sprl proteínas fc multiméricas
CA2941072A1 (en) * 2014-05-02 2015-11-05 Momenta Pharmaceuticals, Inc. Compositions and methods related to engineered fc constructs
GB201412821D0 (en) 2014-07-18 2014-09-03 Liverpool School Tropical Medicine Polymeric proteins and uses thereof
WO2016073917A1 (en) 2014-11-06 2016-05-12 Gliknik Inc. Molecules with bimodal activity depleting target at low dose and increasing immunosuppression at higher dose
EP3265131A1 (en) 2015-03-05 2018-01-10 UCB Biopharma SPRL Polymeric fc proteins and methods of screening to alter their functional characteristics
WO2016179472A2 (en) 2015-05-07 2016-11-10 University Of Maryland, Baltimore Modulation of natural killer cell tolerance
GB201511787D0 (en) 2015-07-06 2015-08-19 Ucb Biopharma Sprl Proteins
GB201513033D0 (en) 2015-07-23 2015-09-09 Ucb Biopharma Sprl Proteins
RU2020138007A (ru) * 2015-07-24 2020-12-17 Гликник Инк. Гибридные белки фрагментов белков человека для создания упорядоченно мультимеризованных композиций областей fc иммуноглобулинов с усиленным связыванием с системой комплемента
GB201515745D0 (en) 2015-09-04 2015-10-21 Ucb Biopharma Sprl Proteins
EP3423572B1 (en) 2016-03-02 2023-11-29 Momenta Pharmaceuticals, Inc. Methods related to engineered fc constructs
KR20190003951A (ko) * 2016-04-04 2019-01-10 바이오버라티브 유에스에이 인코포레이티드 항-보체 인자 bb 항체 및 이의 용도
EP3464347B1 (en) 2016-06-07 2023-05-31 Gliknik Inc. Cysteine-optimized stradomers
EP3487534A4 (en) 2016-07-22 2020-03-25 Gliknik Inc. FUSION PROTEINS FROM HUMAN PROTEIN FRAGMENTS FOR THE PRODUCTION OF MULTIMERIZED IMMUNOGLOBULIN FC COMPOSITIONS WITH INCREASED FC RECEPTOR BINDING
KR20190095929A (ko) 2016-12-09 2019-08-16 글리크닉 인코포레이티드 다합체화 스트라도머인 gl-2045의 제조 최적화
WO2018107082A1 (en) 2016-12-09 2018-06-14 Gliknik Inc. Methods of treating inflammatory disorders with multivalent fc compounds

Also Published As

Publication number Publication date
RU2019117789A (ru) 2020-12-07
EP3551227A4 (en) 2020-07-29
RU2019117789A3 (es) 2021-01-29
CN110022898A (zh) 2019-07-16
AU2017371182A1 (en) 2019-05-23
JP2023063293A (ja) 2023-05-09
BR112019009495A2 (pt) 2019-08-06
AU2017371182B2 (en) 2024-03-28
CA3043251A1 (en) 2018-06-14
US20200069769A1 (en) 2020-03-05
IL266988A (en) 2019-07-31
WO2018107082A1 (en) 2018-06-14
US11331372B2 (en) 2022-05-17
KR20190093186A (ko) 2019-08-08
JP2020500856A (ja) 2020-01-16
CN110022898B (zh) 2023-07-04
EP3551227A1 (en) 2019-10-16
US20220241372A1 (en) 2022-08-04

Similar Documents

Publication Publication Date Title
MX2019006141A (es) Metodos para tratar trastornos inflamatorios con compuestos de fc multivalentes.
MX2021000071A (es) Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer.
MX2017016134A (es) Aril dihidro-2h-benzo[b][1,4]oxazina sulfonamida y compuestos relacionados para uso como agonistas de rory y el tratamiento de enfermedad.
MX2016007111A (es) Inhibidores de tirosina quinasa de bruton.
WO2016196776A3 (en) Inhibitors of bruton's tyrosine kinase
EA201791199A1 (ru) Способ лечения болезни альцгеймера
MX2022011334A (es) Tratamiento de la enfermedad de fabry en pacientes no tratados y tratados previamente con ert.
WO2016004305A3 (en) Inhibitors of bruton's tyrosine kinase
PH12018500762A1 (en) Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof
MX2018015089A (es) Combinacion de linagliptina y metformina.
BR112016000546A2 (pt) métodos para tratar ou prevenir condições oftalmológicas
EA201890891A1 (ru) Биомаркеры, связанные с заболеваниями, опосредованными интерлейкином-33 (ил-33), и их применение
BR112017002637A2 (pt) métodos para tratar ou prevenir condições oftalmológicas
MX2022008181A (es) Composiciones farmaceuticas que comprenden un compuesto de dextrometorfano y quinidina para el tratamiento de agitacion en demencia.
EA201590654A1 (ru) Комбинация разагилина и придопидина для лечения нейродегенеративных нарушений, в частности болезни хантингтона
MX2019005435A (es) Composicion farmaceutica, metodos para tratamiento y sus usos.
MX2018012538A (es) Agonistas del receptor activado por proliferador de peroxisoma (ppar), compuestos, composiciones farmaceuticas y metodos para usar los mismos.
MX2019004280A (es) Organonitro-sulfoalquilo y compuestos relacionados y composiciones farmacéuticas para uso en medicina.
EA201790563A8 (ru) Применение реслизумаба для лечения эозинофильной астмы со степенью тяжести от умеренной до тяжелой
BR112017013674A2 (pt) métodos e composições para tratamento de doenças cerebrais.
NZ773981A (en) Nk-3 receptor antagonists for therapeutic or cosmetic treatment of excess body fat
MX2023005628A (es) Metodos para aumentar y/o estabilizar la funcion cardiaca en pacientes con enfermedad de fabry.
EP4279127A3 (en) Growth differentiation factor 15 as biomarker for metformin
EA202090242A1 (ru) Лечение болезни фабри у фзт-наивных и фзт-леченных пациентов
EA201691567A1 (ru) Способы лечения легких травм головного мозга